Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

Abstract

IntroductionMany studies have demonstrated elevated circulating levels of high-mobility group box 1 (HMGB1) and decreased circulating levels of soluble receptor for advanced glycation end products (sRAGE) in patients with autoimmune diseases. In the present study, we investigated plasma levels of both HMGB1 and sRAGE in primary antiphospholipid syndrome (pAPS) patients.MethodsWe prospectively recruited 11 pAPS patients, 17 antiphospholipid antibody (APA)-positive SLE patients without APS manifestations (APA+SLE) and 12 SLE patients with secondary APS (APS+SLE). We also recruited 10 healthy controls (HCs). Plasma levels of HMGB1 and sRAGE were determined using sandwich ELISA kits. In addition, plasma levels of HMGB1 were also determined using Western blot in 6 pAPS patients and 6 HCs.ResultsThere was no significant difference in plasma levels of HMGB1 measured by ELISA among subgroups of the enrolled subjects. In addition, there was no significant difference in plasma levels of HMGB1 measured by Western blot between pAPS patients and HCs. On the other hand, we observed a trend toward lower plasma levels of sRAGE in APA+SLE or APS+SLE patients when compared with HCs. However, there was no significant difference in plasma levels of sRAGE between pAPS patients and HCs, or between APA+SLE patients and APS+SLE patients.ConclusionThere was no significant difference in plasma levels of sRAGE or HMGB1 between pAPS patients and HCs. Plasma levels of sRAGE/HMGB1 could not be utilized to differentiate between APA+SLE and APS+SLE patients.

Diagnostic value of serum high‐mobility group box‐1 in pediatric systemic lupus erythematosus

“…On the other hand, a previous study demonstrated no significant difference in plasma levels of HMGB1 between adult SLE patients with antiphospholipid antibodies and those with antiphospholipid antibody syndrome (APS) and healthy controls. The authors explained this by interference of anti‐HMGB1 antibodies during ELISA measurement and that anti‐HMGB1 is associated with low serum HMGB1 . However, the present study and several others used the ELISA technique for HMGB1 measurement and did not demonstrate that finding.…”

“…On the other hand, a group of investigators reported that serum HMGB1 was not correlated with markers of SLE flare in their pediatric SLE series . One study even reported lower plasma levels of HMGB1 in adult SLE patients during disease flares with inverse correlation between plasma levels of HMGB1 and serum anti‐dsDNA titers …”

Cellular Response against Oxidative Stress, a Novel Insight into Lupus Nephritis Pathogenesis

“…It is suggested that the receptor has a different role in the initial and progressive stage of the disease [ 47 , 48 ]. In addition, patients with SLE who have antiphospholipid antibodies (APA) or antiphospholipid syndrome (APS) have shown a decrease in sRAGE plasma levels compared to control [ 53 ]. sRAGE level is associated with leukocytes lymphocytes, neutrophils and monocytes number and with C4 levels, but it does not correlate with the presence of autoantibodies.…”

Apoptosis in patients with primary antiphospholipid antibody syndrome

“…We prospectively enrolled 42 patients that included 12 pAPS patients, 17 APA + SLE patients and 13 APS + SLE patients. Most of them had also participated in our previous study on APS patients regarding plasma levels of high‐mobility group box 1 (HMGB1) and soluble receptor for advanced glycation end products (sRAGE) in APS patients . APS was diagnosed based on the revised Sapporo classification criteria .…”

“…As described in our previous study, serum anticardiolipin antibodies (ACA) and anti‐β2‐glycoprotein I antibodies were measured by the enzyme‐linked immunosorbent assay (ELISA) kits (INOVA Diagnostics, Inc, San Diego, CA). Lupus anticoagulant was determined by the clot detection method (Beckman Coulter, Inc, Brea, CA).…”